AstraZeneca’s Tagrisso (osimertinib) lung cancer drug has met its goal in a late-stage study, potentially paving the way for a full approval in major markets.
Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas